Evidence map›Paper›PMID 37296356›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2023

The Effects of NLY01, a Novel Glucagon-Like Peptide-1 Receptor Agonist, on Cuprizone-Induced Demyelination and Remyelination: Challenges and Future Perspectives.

Marjan Gharagozloo, Danny Galleguillos, Larissa Jank, Elias S Sotirchos, Matthew D Smith, Thomas Garton, Swati Kumar, Omar Hussein, Saahith Potluri, Michelle Taylor and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Repurposing medications to prevent psychosis.Npj mental health research · 2025
    Review
  10. From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  11. Article
  12. Review
  13. Review
  14. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2024 · on this map
    Review
  15. Review
  16. Special Issue "Pathophysiology and Treatment of Alzheimer's Disease".International journal of molecular sciences · 2024
    Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Marjan GharagozlooDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. mgharag1@jh.edu.ORCID 0000-0002-2166-4012
Danny GalleguillosDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Larissa JankDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Elias S SotirchosDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Matthew D SmithDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Thomas GartonDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Swati KumarDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Omar HusseinDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Saahith PotluriDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Michelle TaylorDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Catherine SiuDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Jackson W MaceDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Ted DawsonDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Valina L DawsonDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Seulki LeeNeuraly Inc, Gaithersburg, MD, USA.
Peter A CalabresiDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. Calabresi@jhmi.edu.
Johns Hopkins University · USNeural Signals (United States) · US

Funding

Medical Scientist Training ProgramT32GM136577 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ANDREA L COX · 2020 to 2026
$13.4M
The Role of KV1.3 in Effector T cellsR01NS041435 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI CALABRESI, PETER A · 2000 to 2025
$5.8M
NIGMS NIH HHS T32 GM136577NINDS NIH HHS R01 NS041435
6 · The paper itself

Abstract

Recent evidence suggests that the glucagon-like peptide-1 receptor (GLP-1R) agonists have neuroprotective activities in the CNS in animal models of Parkinson's disease, Alzheimer's disease, and multiple sclerosis (MS). This study aimed to investigate whether a novel long-acting GLP-1R agonist, NLY01, could limit demyelination or improve remyelination as occurs in MS using the cuprizone (CPZ) mouse model. Herein, we assessed the expression of GLP-1R on oligodendrocytes in vitro and found that mature oligodendrocytes (Olig2

Indexed as

Demyelinating DiseasesMultiple SclerosisRemyelinationAnimalsCuprizoneDisease Models, AnimalGlucagon-Like Peptide-1 ReceptorMiceMice, Inbred C57BLMyelin SheathCuprizoneGlucagon-Like Peptide-1 ReceptorCuprizoneGLP-1RMSMyelinNLY01Oligodendrocytes

Identifiers

PMID37296356
PMCPMC10457267
OpenAlexW4379985260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.